Despite these hurdles, Goldman Sachs sees positive prospects for the biotechnology company. The firm's analysts believe CSL's strategic investments in its IG franchise and the introduction of new ...

Goldman Sachs' stock has surged 46% in a year, and despite potential interest rate risks, it may reach new 52-week highs in 2025. The global banking and asset management segments are key revenue ...